2018 American Transplant Congress
Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy
Virginia Commonwealth University, Richmond.
Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…2018 American Transplant Congress
Treatment of HCV Infection in Renal Transplant Recipients
Renal Transplant Unit, Instituto de Nefrologia Nephrology, Buenos Aires, Argentina.
HCV infection is associated to chronic hepatitis, cirrhosis, hepatic carcinoma and increased incidence of diabetes. Combination of new antiviral drugs have demonstrated utility in liver…2018 American Transplant Congress
Optimizing Outcomes with a Collaborative Approach after Kidney Transplant in Hepatitis C-Positive Recipients Receiving Hepatitis C-Positive Grafts
Piedmont Transplant Institute, Piedmont Healthcare, Atlanta, GA.
PURPOSE: To evaluate the multidisciplinary approach to HCV treatment in HCV+ kidney recipients receiving HCV+ grafts. METHODS: Single center review of treatment and outcomes in…2018 American Transplant Congress
Decision-Making, Informed Consent, and the Experiences of Recipients of Experimental HCV Positive-to-Negative Renal Transplants
Background: The safety and efficacy of transplanting HCV-infected (HCV+) donor organs into HCV-uninfected recipients (HCV D+/R-) is being studied. Recipient experiences are essential to comprehensively…2018 American Transplant Congress
Intentional Transplantation of Hepatitis C Positive Livers into Hepatitis Negative Recipients- Report of the First Case-Series in the World
Dept. of Surgery, Univ of Massachusetts, Worcester, MA.
Background: The current disparity between supply and demand of liver grafts has dramatically increased the waiting time and mortality on the waiting list. The recent…2018 American Transplant Congress
A Comparison of the Discard Rate in Hepatitis C Deceased Liver Donors between Two Eras, 2008-2013 and 2014-2017. A Single Organ Procurement Organization Experience
With the introduction of new hepatitis C medications in 2014 , there is a growing concern for an increase in the discard rate of hepatitis…2017 American Transplant Congress
Pharmakokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV Positive Kidney Transplant Recipients.
BackgroundLimited data exist on the pharmacokinetic (PK) profile of novel direct acting antivirals in kidney transplant recipients (KTR). Here we report the PK of combinated…2017 American Transplant Congress
Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER] Trial.
University of Pennsylvania, Philadelphia
Background: More than 500 kidneys from HCV+ deceased donors are discarded each year, even though direct acting antiviral therapies have cure rates exceeding 95%. We…2017 American Transplant Congress
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.
University of Maryland Medical Center, Baltimore, MD
Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…2017 American Transplant Congress
EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.
Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 28
- Next Page »